Yang (Carsten) Lu, Adlai Nortye CEO
With its ex-Novartis cancer drug near the finish line, Adlai Nortye raises $97.5M in Nasdaq debut
The Nasdaq is welcoming another company hustling along a late-stage drug, with Adlai Nortye raising $97.5 million from an IPO and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
